Allergy Asthma Immunol Res.  2016 Nov;8(6):479-480. 10.4168/aair.2016.8.6.479.

Factors Predicting Recovery From Asthma Exacerbations

• Jung CG
• Park HS

• KMID: 2349986
• DOI: http://doi.org/10.4168/aair.2016.8.6.479

Abstract

No abstract available.

MeSH Terms

Asthma*

Reference

1. Lee T, Kim J, Kim S, Kim K, Park Y, Kim Y, et al. Risk factors for asthma-related healthcare use: longitudinal analysis using the NHI claims database in a Korean asthma cohort. PLoS One. 2014; 9:e112844.

2. Watase H, Hagiwara Y, Chiba T, Camargo CA Jr, Hasegawa K. Japanese Emergency Medicine Network Investigators. Multicentre observational study of adults with asthma exacerbations: who are the frequent users of the emergency department in Japan? BMJ Open. 2015; 5:e007435.

3. Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol. 2011; 128:1165–1174.

4. Greenberg S. Asthma exacerbations: predisposing factors and prediction rules. Curr Opin Allergy Clin Immunol. 2013; 13:225–236.

5. Quezada W, Kwak ES, Reibman J, Rogers L, Mastronarde J, Teague WG, et al. Predictors of asthma exacerbation among patients with poorly controlled asthma despite inhaled corticosteroid treatment. Ann Allergy Asthma Immunol. 2016; 116:112–117.

6. Rank MA, Hagan JB, Park MA, Podjasek JC, Samant SA, Volcheck GW, et al. The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013; 131:724–729.

7. Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015; 45:396–407.

8. Williams LK, Pladevall M, Xi H, Peterson EL, Joseph C, Lafata JE, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol. 2004; 114:1288–1293.

9. Jackson DJ, Johnston SL. The role of viruses in acute exacerbations of asthma. J Allergy Clin Immunol. 2010; 125:1178–1187.

10. Bousquet J, Gaugris S, Kocevar VS, Zhang Q, Yin DD, Polos PG, et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected]. Clin Exp Allergy. 2005; 35:723–727.

11. Zeiger RS, Schatz M, Li Q, Chen W, Khatry DB, Gossage D, et al. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. J Allergy Clin Immunol Pract. 2014; 2:741–750.

12. Ciółkowski J, Mazurek H, Hydzik P, Stasiowska B. Inflammatory markers as exacerbation risk factors after asthma therapy switch from inhaled steroids to montelukast. Pulm Pharmacol Ther. 2016; 39:7–13.

13. Song WJ, Kwon JW, Kim EJ, Lee SM, Kim SH, Lee SY, et al. Clinical application of exhaled nitric oxide measurements in a korean population. Allergy Asthma Immunol Res. 2015; 7:3–13.

14. Lee KY, Lee KS, Park SJ, Kim SR, Min KH, Choe YH, et al. Clinical significance of plasma and serum vascular endothelial growth factor in asthma. J Asthma. 2008; 45:735–739.

15. Sigari N, Jalili A, Mahdawi L, Ghaderi E, Shilan M. Soluble CD93 as a novel biomarker in asthma exacerbation. Allergy Asthma Immunol Res. 2016; 8:461–465.

16. Kim HJ, Lee J, Kim JH, Park SY, Kwon HS, Kim TB, et al. Factors affecting recovery time of pulmonary function in hospitalized patients with acute asthma exacerbations. Allergy Asthma Immunol Res. 2016; 8:499–504.

17. Sekiya K, Taniguchi M, Fukutomi Y, Watai K, Minami T, Hayashi H, et al. Age-specific characteristics of inpatients with severe asthma exacerbation. Allergol Int. 2013; 62:331–336.

18. Hasegawa K, Gibo K, Tsugawa Y, Shimada YJ, Camargo CA Jr. Age-related differences in the rate, timing, and diagnosis of 30-day readmissions in hospitalized adults with asthma exacerbation. Chest. 2016; 149:1021–1029.